Coverage Initiated by Evercore ISI – 2 stars for Viridian Therapeutics (VRDN)

Stock analysts at Evercore ISI – 2 stars initiated coverage on shares of  Viridian Therapeutics (VRDN) in a report issued on monday. The brokerage set a Outperform rating on the Medical stock. A price-to-earnings ratio of #N/A and a beta of 17.02. Viridian Therapeutics has a twelve month low $7.08 of  and a twelve month high of $25.67.

Shares of Viridian Therapeutics traded down -$0.55 on monday, reaching $15.65. 7 shares of the stock traded hands, compared to its average volume of 355244. Shares of Viridian Therapeutics were trading at $15.65 on monday. The firm’s 50 day moving average is $$13.88 and its 200 day moving average is $16.81.Viridian Therapeutics  has a 12 month low of $15.62 and a 12 month high of $25.67. While on yearly highs and lows, Viridian Therapeutics’s today has traded high as $16.51 and has touched $15.62 on the downward trend. See More Analyst Rating at: RATING

Viridian Therapeutics Earnings and What to expect: 

Viridian Therapeutics last posted its quarterly earnings data on August 11th, 2021. The reported ($2.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.36) by $0.85. The firm had revenue of $1.09 million for the quarter. Viridian Therapeutics has generated ($11.49) earnings per share over the last year (($29.69) diluted earnings per share). Earnings for Viridian Therapeutics are expected to grow in the coming year, from ($5.88) to ($2.99) per share. Viridian Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 9th, 2021 based off prior year’s report dates.

Earnings for Viridian Therapeutics are expected to grow in the coming year, from ($5.88) to ($2.99) per share. The P/E ratio of Viridian Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Viridian Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Latest Insiders Trading and Volume : 

  • On at average share price of which equates to in money value.
  • On at average price of  with total value of :
  • On at average price of  with total value of :

Analyt at Evercore ISI – 2 stars other ratings :

Latest rating for Viridian Therapeutics by other brokers:

Viridian Therapeutics (VRDN) Moving Average Technical Analysis

5 day Moving Average is $16.83 And 5 day price change is -$1.84 (-10.52%)  with average volume for 5 day average is 137,640. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $15.02 and 20 day price change is $3.22 (25.91%) and average 20 day moving volume is 468,295. 50 day moving average is $13.88  and 50 day price change is $0.13 ( 0.81%)  and with average volume for 50 days is : 250,492. 200 day moving average is $16.81  and 200 day price change is -$2.67 (-14.57%)  and with average volume for 200 days is : 94,046.

See More Analyst Rating at: RATING